Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C
virus (HCV) genotype 4, the most common type in Egypt, according to findings
from the Pyramid 1 study presented at the Conference on Retroviruses and
Opportunistic Infections (CROI 2016) last month in Boston.
Direct-acting antiviral agents used in interferon-free regimens have
revolutionised treatment for chronic hepatitis C, but there is still a need for
better therapies for harder-to-treat patients. Ideally treatment would be
pan-genotypic, or active against all HCV types, so it could be routinely
prescribed in resource-limited settings without the need for genotype testing.
Imam Waked of the
National Liver Institute in Egypt reported results from Pyramid 1, a phase 3
study evaluating Gilead Sciences’ HCV NS5B polymerase inhibitor sofosbuvir (Sovaldi) and the pan-genotypic NS5A
inhibitor ravidasvir for people with genotype 4 hepatitis C. Ravidasvir, formerly known as PPI-668, is being
co-developed by Pharco Pharmaceuticals in Egypt
and Presidio Pharmaceuticals in San Francisco.
HCV genotype 4 accounts for 15% of all chronic hepatitis C cases worldwide
and is the predominant type throughout the Middle East and parts of Africa,
Waked noted as background. More than 90% of Egyptians with hepatitis C have
this genotype, but it accounts for a small proportion of cases in the US,
Europe and Asia, and has not been as extensively studied as genotype 1.
Pyramid 1 enrolled 300 people with genotype 4 chronic hepatitis C in
Egypt. Nearly 70% were men and the mean age was approximately 48 years. Half
were previously untreated and half had received prior interferon-based therapy.
More than 40% had compensated liver cirrhosis.
Participants were stratified according to prior treatment and cirrhosis
- Group 1a (n = 90): treatment-naive without cirrhosis
- Group 1b (n = 60): treatment-naive with cirrhosis
- Group 2 (n = 80): treatment-experienced without
- Group 3 (n = 70): treatment-experienced with cirrhosis
Participants in groups 1a, 1b and 2 received 200mg ravidasvir and 400mg
sofosbuvir, both taken once daily for 12 weeks, and were randomly assigned to either
add ribavirin or not. The harder-to-treat patients in group 3 received
ravidasvir plus sofosbuvir and ribavirin for either 12 or 16 weeks.
Among participants without cirrhosis treated with ravidasvir and
sofosbuvir alone, 100% of previously untreated and 95% of treatment-experienced
participants achieved sustained virological response, or continued undetectable
viral load at 12 weeks after completion of treatment (SVR12). Among those who
added ribavirin, SVR12 rates were 98 and 100%, respectively.
Looking at treatment-naive participants with cirrhosis, SVR12 rates were
93% with ravidasvir and sofosbuvir alone and 92% with the addition of
ribavirin. Among the treatment-experienced participants with cirrhosis, only
86% were cured with ravidasvir, sofosbuvir and ribavirin taken for 12 weeks,
but the SVR12 rate rose to 100% when treatment was extended to 16 weeks.
No relapses occurred among participants without cirrhosis, and all
treatment failures were due to early discontinuation. The highest relapse rate –
10.5% – was seen in the treatment-experienced group with cirrhosis, treated for
12 weeks (including one participant who discontinued due to an adverse event
after 8 weeks), but there were no relapses with 16-week treatment.
Treatment was generally safe and well-tolerated. There was one serious
adverse event, bradycardia (slow heartbeat), considered to be probably related
to study drugs; this participant discontinued treatment at week 8 and the
abnormality resolved. The most common adverse events were headache (13%),
abdominal discomfort (6%), fatigue (5%), itching (4%) and diarrhoea (2%). Three
people taking ribavirin developed anaemia and two lowered their ribavirin dose.
Ravidasvir plus sofosbuvir with or without ribavirin “shows high sustained response
rates” in this largest-ever study of interferon-free therapy for people with
genotype 4 HCV, with the highest proportion of people with cirrhosis, the
researchers concluded. Adding ribavirin did not improve response rates for
people without cirrhosis or previously untreated patients.